31 Myalgic Encephalomyelitis Clinical Trials in Orlando, FL (2026)

Q: How do I join a clinical trial in Orlando?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Orlando research site will contact you.

Recruiting Myalgic Encephalomyelitis Studies in Orlando

NCT06876857Recruiting

University of Central Florida CereBank

Millions of persons are affected by brain diseases. The CereBank will be used to support research studies aimed at improving the diagnosis and treatment of brain diseases. Brain diseases can be inheri...

Orlando, FL50,000 participantsUniversity of Central Florida

View Study Details

NCT05685745Recruiting

Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset

The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and practices for all deliveri...

Orlando, FL5,000 participantsThe University of Texas Health Science Center, Houston

View Study Details

NCT04291612Recruiting

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema....

Orlando, FL1,715 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06584357Recruiting

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective....

Orlando, FL1,200 participantsGAP Innovations, PBC

View Study Details

NCT06952504Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues ...

Orlando, FL1,123 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07044336Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or p...

Orlando, FL800 participantsAstraZeneca

View Study Details

NCT05727904Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab al...

Orlando, FL670 participantsIovance Biotherapeutics, Inc.

View Study Details

NCT05549297Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including cli...

Orlando, FL540 participantsImmunocore Ltd

View Study Details

NCT06545331Recruiting

Study of XB010 in Subjects With Solid Tumors

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with lo...

Orlando, FL396 participantsExelixis

View Study Details

NCT05397639Recruiting

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the...

Orlando, FL375 participantsSuven Life Sciences Limited

View Study Details

NCT05245500Recruiting

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy wit...

Orlando, FL336 participantsBristol-Myers Squibb

View Study Details

NCT06719141Recruiting

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and...

Orlando, FL320 participantsLongboard Pharmaceuticals

View Study Details

NCT05462106Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with...

Orlando, FL304 participantsAC Immune SA

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

Orlando, FL290 participantsCrescent Biopharma, Inc.

View Study Details

NCT05066217Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult p...

Orlando, FL260 participantsEpygenix

View Study Details

NCT05219617Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in ped...

Orlando, FL252 participantsSK Life Science, Inc.

View Study Details

NCT07205718Recruiting

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 m...

Orlando, FL223 participantsTakeda

View Study Details

NCT06872125Recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome....

Orlando, FL170 participantsStoke Therapeutics, Inc

View Study Details

NCT07227298Recruiting

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor ...

Orlando, FL162 participantsPfizer

View Study Details

NCT06660394Recruiting

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and a...

Orlando, FL160 participantsLongboard Pharmaceuticals

View Study Details

NCT04696029Recruiting

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma....

Orlando, FL118 participantsGiselle Sholler

View Study Details

NCT06307795Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in particip...

Orlando, FL63 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT06481592Recruiting

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer....

Orlando, FL60 participantsIovance Biotherapeutics, Inc.

View Study Details

NCT05361174Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC)....

Orlando, FL53 participantsIovance Biotherapeutics, Inc.

View Study Details

NCT07096843Recruiting

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN...

Orlando, FL45 participantsClimb Bio, Inc.

View Study Details

NCT07385547Recruiting

Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency

This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximate...

Orlando, FL40 participantsSun Pharmaceutical Industries Limited

View Study Details

NCT07217886Recruiting

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

The purpose of this study is to measure the pharmacokinetics, safety, and tolerability of S-892216 (S-892216-PO) in participants with mild, moderate, or severe renal impairment not on dialysis, or ren...

Orlando, FL40 participantsShionogi

View Study Details

NCT06189963Recruiting

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 ...

Orlando, FL36 participantsNKGen Biotech, Inc.

View Study Details

NCT02235857Recruiting

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma ch...

Orlando, FL35 participantsKaneka Medical America LLC

View Study Details

NCT06442436Recruiting

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to th...

Orlando, FL32 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07324616Recruiting

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus partici...

Orlando, FL32 participantsEdgewise Therapeutics, Inc.

View Study Details

About Myalgic Encephalomyelitis Clinical Trials in Orlando

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 31 myalgic encephalomyelitis clinical trials recruiting participants in Orlando, FL. These studies are seeking a combined 64,850 participants. Research is being sponsored by University of Central Florida, The University of Texas Health Science Center, Houston, Memorial Sloan Kettering Cancer Center and 24 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Orlando — FAQ

Are there myalgic encephalomyelitis clinical trials in Orlando?

Yes, there are 31 myalgic encephalomyelitis clinical trials currently recruiting in Orlando, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Orlando?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orlando research site will contact you about next steps.

Are clinical trials in Orlando free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orlando studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 31 active trials in Orlando are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated July 13, 2026 from ClinicalTrials.gov